24/7
-
-over selected period
-since US close
Price differences before fees and execution costs. Compare prices
Novo Nordisk said it will present 26 abstracts at ObesityWeek 2026, including new data on its obesity treatment pipeline and real-world experience with Wegovy.
prnewswire.com ·
BioSpace reports Eli Lilly's retatrutide beat Novo Nordisk's Ozempic in weight loss and blood sugar reduction in a trial, with a regulatory application expected in the first quarter of 2027.
biospace.com ·
Benzinga reports Novo Nordisk failed in its court bid to block Eli Lilly's weight-loss drug ads, with the judge finding little evidence of market impact or lasting harm.
benzinga.com ·
Novo Nordisk announced it will present 12 new abstracts of real-world and clinical semaglutide data at the AASLD Liver Meeting in November 2026.
prnewswire.com ·
Seeking Alpha reports that Eli Lilly's experimental obesity drug retatrutide beat Novo Nordisk's Ozempic in a late-stage clinical trial.
seekingalpha.com ·
Hold NVOc in a Mo smart wallet on Base that you control.
Send NVOc to another Mo user for free, or transfer to any compatible Base wallet near-instantly.
